Overview

The Efficacy and Safety of CC-10004 in Chronic Cutaneous Sarcoidosis

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
To determine whether CC-10004, a phosphodiesterase inhibitor, is useful in treating chronic cutaneous sarcoidosis.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University of Cincinnati
Collaborators:
Celgene Corporation
Medical University of South Carolina
Treatments:
Apremilast
Thalidomide